Subcutaneous belimumab effective in lupus subgroup

Subcutaneous belimumab improves outcomes in anti-double-stranded DNA-positive patients with systemic lupus erythematosus (SLE) and low complement levels, according to results from a phase 3 randomised controlled trial.